BioNexus Gene Lab Corp. (BGLC)
NASDAQ: BGLC · Real-Time Price · USD
1.820
+0.250 (15.92%)
Aug 17, 2026, 4:00 PM EDT - Market closed
BioNexus Gene Lab Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3.13 | 7.42 | 9.51 | 9.77 | 10.93 | 13.36 | |
Revenue Growth | -67.27% | -21.93% | -2.66% | -10.60% | -18.21% | 17.31% |
Cost of Revenue | 2.74 | 6.34 | 8.22 | 8.44 | 9.67 | 11.1 |
Gross Profit | 0.39 | 1.09 | 1.29 | 1.33 | 1.26 | 2.27 |
Selling, General & Admin | 1.93 | 3.27 | 3.86 | 3.04 | 1.73 | 1.28 |
Research & Development | 0.05 | 0.05 | 0.05 | 0.05 | - | - |
Other Operating Expenses | 0.03 | -0.06 | -0.06 | -0.04 | -0.25 | -0.07 |
Operating Expenses | 3.14 | 4.18 | 3.19 | 4.37 | 1.48 | 1.21 |
Operating Income | -2.76 | -3.1 | -1.9 | -3.04 | -0.22 | 1.06 |
Interest Expense | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
Interest & Investment Income | 0.07 | 0.11 | 0.22 | 0.13 | - | - |
Currency Exchange Gain (Loss) | -0.09 | -0.09 | - | - | - | - |
Other Non Operating Income (Expenses) | 0 | 0 | - | - | - | - |
EBT Excluding Unusual Items | -2.79 | -3.11 | -1.7 | -2.92 | -0.23 | 1.04 |
Gain (Loss) on Sale of Investments | 0.21 | 0.12 | 0.11 | 0.31 | -0.07 | - |
Pretax Income | -2.58 | -2.98 | -1.59 | -2.61 | -0.3 | 1.04 |
Income Tax Expense | - | - | 0 | 0.02 | 0.05 | 0.29 |
Net Income | -2.58 | -2.98 | -1.6 | -2.63 | -0.36 | 0.75 |
Net Income to Common | -2.58 | -2.98 | -1.6 | -2.63 | -0.36 | 0.75 |
Net Income Growth | - | - | - | - | - | -31.31% |
Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 1 | 1 |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 1 | 1 |
Shares Change | 20.61% | 4.20% | 12.24% | 10.17% | 0.99% | 66.36% |
EPS (Basic) | -1.19 | -1.61 | -0.90 | -1.66 | -0.25 | 0.53 |
EPS (Diluted) | -1.19 | -1.61 | -0.90 | -1.66 | -0.25 | 0.53 |
EPS Growth | - | - | - | - | - | -58.71% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -0.85 | -1.88 | -2.32 | -1.97 | 0.5 | 0.01 |
Free Cash Flow Per Share | -0.39 | -1.01 | -1.30 | -1.24 | 0.34 | 0.00 |
Gross Margin | 12.34% | 14.62% | 13.56% | 13.61% | 11.52% | 16.96% |
Operating Margin | -88.16% | -41.74% | -19.95% | -31.09% | -2.02% | 7.90% |
Profit Margin | -82.36% | -40.20% | -16.81% | -26.91% | -3.26% | 5.62% |
Free Cash Flow Margin | -27.30% | -25.26% | -24.40% | -20.18% | 4.55% | 0.04% |
EBITDA | -2.64 | -2.99 | -1.79 | -2.95 | -0.13 | 1.15 |
EBITDA Margin | -84.44% | -40.23% | -18.86% | -30.24% | -1.18% | 8.58% |
D&A For EBITDA | 0.12 | 0.11 | 0.1 | 0.08 | 0.09 | 0.09 |
EBIT | -2.76 | -3.1 | -1.9 | -3.04 | -0.22 | 1.06 |
EBIT Margin | -88.16% | -41.74% | -19.95% | -31.09% | -2.02% | 7.90% |
Effective Tax Rate | - | - | - | - | - | 27.93% |